An observational study in Atrial Fibrillation, sponsored by National Research Center for Preventive Medicine. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-29.
Sponsored by National Research Center for Preventive Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Atrial Fibrillation with a site in Russian Federation — 4 open to participants now, 5 under way, none of them phase 3. Atrial Fibrillation · Russian Federation.
Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, this one is the 18th largest by enrollment of the 26 observational ones that give a count, is one of 6 that started in 2018, is one of 26 observational ones, and was the 84th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 107 studies in Atrial Fibrillation with a site in Russian Federation are open now. Recruiting first, the newest first:
Vasily I. Kaleda · Sites in Russian Federation
Ages 18+
Saint Petersburg State University, Russia · Sites in Russian Federation
Ages 18+
Meshalkin Research Institute of Pathology of Circulation · Sites in Russian Federation
Ages 18–80
Center for Strategic Planning, of the Federal Medical and Biological Agency · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 28 · Phase 4 10
First in 2001; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is close to the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 175 across the 80 interventional studies, 1,063 across the 26 observational. Of the 80 that completed or were terminated, 27 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 107 have an industry lead sponsor. The 10 most frequent:
National Research Center for Preventive Medicine is the lead sponsor of 18 studies on the registry; none are open to participants now.
National Research Center for Preventive Medicine has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies in Atrial Fibrillation with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920226Ryazan State Medical UniversityMyocardial Fibrosis in Patients With Permanent Pacemakers | 2027-07-01 |
| NCT06823778Vasily I. KaledaProphylactic Radiofrequency Left Atrial Posterior Wall Isolation to Prevent Atrial Fibrillation After Cardiac Surgery | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Left atrial appendage (LAA) occlude devices are used for over ten years. According to current data efficiency and safety of this approach at least comparable with pharmacological prevention of stroke in patients with non-valvular atrial fibrillation.
However, to date, LAA occluder implantation is not recommended as an alternative for conservative therapy and reserved for patients with contraindications for oral anticoagulants only. In the same time, long-term follow-up of patients enrolled in clinical trials and data from registries showed that LAA occlude device implantation as an alternative to oral anticoagulation could reduce drug load, decrease complexity and cost of treatment and thus improve patients' quality of life, and potentially may reduce the risk of death. The aim of our study is to investigate the risk of all-cause death, stroke, and bleedings in patients with LAA occluder implanted as an alternative to anticoagulant therapy.
Three hundred patients with atrial fibrillation will undergo LAA occluder implantation. For LAA occluder sizing transesophageal echocardiography (TEE), CT and LAA angiography will be performed. The follow-up period will be 36 months. The incidence of all-cause death, stroke, bleeding BARC≥2, device-related complications and QOL will be investigated.
The patients will be followed in the clinic at three and six months, and then at 12, 24 and 36 months, the telephone calls for getting information about endpoints events will be done. Additional in clinic visits will be scheduled if the late complications will be suspected.
TEE will be performed at three and six months to check for device leak, displacement and thrombosis.
Patients >18 years old with atrial fibrillation and high risk for tromboembolic events
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients will get implantation of LAA occluder
Number of patients with Composite of death, stroke, clinically significant bleeding event (>_2 class according to BARC criteria), device leak, device displacement or device thrombosis with the first event for a given patient is taken into account
a clinically significant bleeding event is \>_2 class according to Bleeding Academic Research Consortium (BARC) criteria bleeding
Time frame: 36 months
device thrombosis during first 6 months
device thrombosis detected by transesophageal echocardiography during first 6 months of follow-up
Time frame: 6 months
device dislocation
number of patients who would have device dislocation
Time frame: 36 months
any bleed
total number of patients who would have any bleeding event
Time frame: 36 months
bleeding BARC ≥2
total number of patients who would have bleeding event with the grade BARC ≥2
Time frame: 36 months
device leak and displacement during first 6 months
device leak detected by transesophageal echocardiography during first 6 months after implantation or device displacement during the same time period
Time frame: 6 months
any adverse events during 7 days after LAA occluder implantation
any adverse events related to the device implantation during the first 7 days after implantation
Time frame: 7 days
change in QOL SF 36 between baseline and final visit
change in quality of life (QOL) by Short Form (SF) 36 Health Survey between baseline and follow-up visits SF 36 is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health. 0-100 scale are using to access each domain. lower the score the more disability.
Time frame: Assessed at baseline and 6-month follow-up visits
the percent of patients in whom long -term anticoagulation therapy would add during follow-up
number of patients who would require adding permanent anticoagulant therapy for any reason during follow-up
Time frame: 36 months
Ran from Dec 2018 to primary completion in Dec 2021, 36 months.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 36 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Research Center for Preventive Medicine